Hydrogenology
Hydrogenology editorial study record

Hydrogen in drinking water reduces dopaminergic neuronal loss in the MPTP mouse model of Parkinson's disease

Fujita K et al. · PLoS One. 2009;4(9):e7247.

PreclinicalH₂-rich waterPublished 2009
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Preclinical

Reported design

Controlled acute and chronic MPTP mouse experiments with H₂ concentration response

Research topic

Parkinson’s disease

Administration classification

H₂-rich water

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Mice exposed to acute injections or chronic infusion of MPTP

Sample

Individual experiments commonly used n=4–6/group

Duration

Water began before acute or chronic MPTP exposure and continued through scheduled behavioral and tissue assessments

Intervention

Ad libitum H₂-containing drinking water prepared by H₂ bubbling or magnesium reaction

Hydrogen form

H₂ dissolved in drinking water — H₂ only, not Brown’s gas and not inhalation.

H₂ specification

0.04, 0.08, 0.5 and 1.5 ppm were studied; 0.08 ppm was reported to produce an effect similar to 1.5 ppm in the concentration experiment.

H₂ flow

Not applicable — oral water, not gas inhalation.

O₂ delivered with H₂

No O₂ was co-delivered as part of the intervention.

Comparator

MPTP and saline groups receiving non-H₂ water

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Dopaminergic neurons, motor activity, 8-oxoG, 4-HNE and superoxide signal

Reported result

H₂ water was associated with preservation of dopaminergic neurons and lower 8-oxoG and 4-HNE. Superoxide detected with DHE was not significantly reduced.

Results-extraction completeness

Concentration response, methods, figures and positive and null results checked in the open-access full text.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Multiple small mouse experiments, laboratory outcomes and no patients. It cannot establish prevention or treatment of human Parkinson’s disease.

Applies directly to

MPTP mouse models of dopaminergic injury, not people with Parkinson’s disease.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 19789628 · DOI: 10.1371/journal.pone.0007247

Publisher access

Open-access full text is available through PMC.

Extraction basis

Open-access PMC full text and PubMed record.

Record revision

2026-08-10

Open bibliographic source ↗Open lawful free full text ↗Report a discrepancy